Skip to Content

Gabriela Rondon, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Gabriela Rondón is an Associate Professor in the Department of Stem Cell Transplantation and Cellular Therapy at the M. D. Anderson Cancer Center in Houston, Texas. She completed her Post Doctoral fellowship training here at the University of Texas M. D. Anderson, and began her tenure in 1995. She has made important clinical observations resulting in the description of a “graft versus leukemia effect in CLL” as well as defining the role of different strategies for treatment of graft failure that has led to our current “standards of practice” within the department. She also developed our current guidelines for adverse event reporting in the context of high dose therapy and stem cell transplantation. These guidelines led to a more homogeneous and relevant reporting of adverse outcomes in these settings of high dose therapy and stem cell transplantation. Dr. Rondón has been a close collaborator of Dr. Martin Korbling in his research related to the potential role of stem cell plasticity. In recent years she has instituted a prospective toxicity grading system by the protocol research staff for all SCTCT clinical trials, which has markedly improved the objectivity and responsibility of toxicity grading. As the Director of Protocol Research and Data Management. She has been actively involved in implementing strategies to assure successful protocol development and execution. She has also lead one of our most important obligations related to our data management activities with the Center for International Blood and Marrow Transplant Research (CIBMTR) and is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, and American Society for Blood and Marrow Transplantation.


Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 423
Houston, TX 77030
Room Number: Faculty Center, FC5.3010

Education & Training

Degree-Granting Education

1985 Universidad Central de Venezuela, Caracas, Venezuela, MedicoCirujano, Medicine

Postgraduate Training

9/1992-9/1994 Post-Doctoral Fellow, Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, M. Andreeff
10/1991-9/1992 Post-Doctoral Fellow, Pheresis and Bone Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, J Hester
8/1986-1/1987 Post -Doctoral Fellow, Pharmacology & Cell Biophysics, University of Cincinnati, Cincinnati, OH, J Hartman


Academic Appointments

Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 8/2003-8/2011

Institutional Committee Activities

Chair, Data Governance Sub-Committee, 12/2014-present
Vice-Chair, Institutional Review Board 1, 8/2014-present
Member, HRPP Protocol Build Committee, 2014-present
Co-author with Dr. John Freedman, Institutional Review Board Policy Reporting Adverse Events, 2012-present

Honors and Awards

1999 Excellence in Data Management, M.D. Anderson Cancer Center Office of Protocol Research Quality Assurance

Selected Publications

Peer-Reviewed Original Research Articles

1. Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, Cardenas-Turanzas M, Price KJ, Champlin RE, Nates JL. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit. J Clin Oncol 31(33):4207-14, 11/2013. e-Pub 10/2013. PMID: 24127454.
2. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 10/2013. e-Pub 7/2013. PMID: 23872222.
3. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 9/2013. e-Pub 7/2013. PMID: 23749720.
4. Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R, Ferguson J, Westmoreland M, Rondon G, Kebriaei P. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. e-Pub 9/2013. PMID: 24022408.
5. Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RF. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 68(8):1872-80, 8/2013. e-Pub 4/2013. PMID: 23572228.
6. Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 13(4):485-92, 8/2013. e-Pub 6/2013. PMID: 23769669.
7. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-64, 7/2013. e-Pub 4/2013. PMID: 23644077.
8. Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB. Ex Vivo T Cell Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission. Biol Blood Marrow Transplant 19(6):898-903, 6/2013. e-Pub 3/2013. PMID: 23467126.
9. Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-70, 5/2013. e-Pub 10/2012. PMID: 23085830.
10. Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 88(4):301-5, 4/2013. e-Pub 3/2013. PMID: 23460378.
11. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol 88(3):198-200, 3/2013. e-Pub 1/2013. PMID: 23345254.
12. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 3/2013. e-Pub 11/2012. PMID: 23128322.
13. Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt S. Dose intensification of Busulfan in the preparative regimen is associated with improved survival: A Phase I/II Controlled, Randomized Study. Biol Blood Marrow Transplant 19(3):474-80, 3/2013. e-Pub 12/2012. PMID: 23220013.
14. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2/2013. e-Pub 9/2012. PMID: 22982533.
15. Cheng YC, Rondón G, Anderlini P, Khouri IF, Champlin RE, Ueno NT. Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. J Cancer 4(8):679-85, 2013. e-Pub 9/2013. PMCID: PMC3805996.
16. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 12/2012. PMID: 23234514.
17. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T-cell Replete Graft Compared with T-cell Depleted Haploidentical Hematopoietic Stem-Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 12/2012. e-Pub 7/2012. PMID: 22796535.
18. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 11/2012. e-Pub 5/2012. PMID: 22643322.
19. Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma 53(8):1525-9, 8/2012. e-Pub 3/2012. PMID: 22242817.
20. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-6, 5/2012. e-Pub 1/2012. PMID: 21988645.
21. Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant 18(4):584-92, 4/2012. e-Pub 8/2011. PMID: 21867666.
22. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 3/2012. e-Pub 1/2012. PMID: 22231283.
23. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged 70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 1/2012. e-Pub 8/2011. PMID: 21780997.
24. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. Hum Gene Ther. e-Pub 1/2012. PMID: 22107246.
25. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, Champlin RE, Alousi AM. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 47(1):125-31, 1/2012. e-Pub 3/2011. PMID: 21383686.
26. Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 12/2011. e-Pub 5/2011. PMID: 21684343.
27. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 118(22):5957-64, 11/2011. e-Pub 10/2011. PMID: 21967975.
28. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. e-Pub 11/2011. PMID: 22086552.
29. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. Biol Blood Marrow Transplant 17(10):1490-6, 10/2011. e-Pub 2/2011. PMID: 21338705.
30. Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO. Reversible Ureteral Obstruction due to Polyomavirus Infection after Percutaneous Nephrostomy Catheter Placement. Biol Blood Marrow Transplant 17(10):1551-5, 10/2011. e-Pub 3/2011. PMID: 21396475.
31. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-7, 3/2011. e-Pub 12/2010. PMID: 21156844.
32. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DR. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol 2011:601953, 2011. e-Pub 11/2011. PMCID: PMC3216266.
33. Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, de Lima M, Shpall EJ, Champlin RE. Lymphocyte Recovery Predicts Outcomes in Cord Blood and T-Cell Depleted Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 11/2010. PMID: 21126598.
34. Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant. e-Pub 10/2010. PMID: 20946966.
35. Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Cano P, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors Using HLA Typing at 10 Loci. Biol Blood Marrow Transplant. e-Pub 10/2010. PMID: 20969970.
36. Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer 116(15):3631-7, 8/2010. PMID: 20564073.
37. Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 16(5):686-694, 5/2010. e-Pub 1/2010. PMID: 20056165.
38. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 3/2010. e-Pub 8/2009. PMID: 19668237.
39. Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol 90(5):627-34, 12/2009. e-Pub 12/2009. PMID: 19998065.
40. Nakayama K, Liu P, Detry M, Schover LR, Milbourne A, Neumann J, Rondon G, Thewes B, Champlin RE, Ueno NT. Receiving information on fertility-and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. Biol Blood Marrow Transplant 15(11):1465-74, 11/2009. PMID: 19822307.
41. Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 10/2009. e-Pub 8/2009. PMID: 19654407.
42. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1094-9, 9/2009. PMID: 19660722.
43. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 44(2):81-7, 7/2009. e-Pub 5/2009. PMID: 19448681.
44. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 15(5):610-7, 5/2009. PMID: 19361753.
45. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43(9):685-92, 5/2009. e-Pub 11/2008. PMID: 19011667.
46. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144-52, 4/2009. e-Pub 1/2009. PMID: 19168784.
47. Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 94(2):249-57, 2/2009. e-Pub 1/2009. PMCID: PMC2635398.
48. Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. PMID: 19778850.
49. Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant 14(8):859-66, 8/2008. PMID: 18640568.
50. Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IF. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 40(5):431-5, 9/2007. PMID: 17603511.
51. Patah PA, Parmar S, McMannis J, Sadeghi T, Karandish S, Rondon G, Tarrand J, Champlin R, de Lima M, Shpall EJ. Microbial contamination of hematopoietic progenitor cell products: clinical outcome. Bone Marrow Transplant 40(4):365-8, 8/2007. PMID: 17572714.
52. Ueno NT, Konoplev S, Buchholz TA, Smith T, Rondon G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin RE. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant 37:929-35, 5/2006. PMID: 16565737.
53. Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica 90(12):1725-6, 12/2005. PMID: 16330461.
54. Cheng YC, Rondon G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 10(11):794-804, 11/2004. PMID: 15505610.
55. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 10(3):178-85, 3/2004. PMID: 14993883.
56. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 11/2003. PMID: 12881308.
57. Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NT. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 31(12):1157-63, 6/2003. PMID: 12796796.
58. Montemurro F, Rondon G, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NT. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant 9(5):330-40, 5/2003. PMID: 12766883.
59. Ueno NT, Anagnostopoulos A, Rondon G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 119(1):131-4, 10/2002. PMID: 12358917.
60. Montemurro F, Rondon G, Ueno NT, Munsell M, Gajewski JL, Champlin RE. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 29(10):861-6, 5/2002. PMID: 12058236.
61. Korbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med 346(10):738-46, 3/2002. PMID: 11882729.
62. Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 8(10):550-6, 2002. PMID: 12434950.
63. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondon G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7(12):4008-12, 12/2001. PMID: 11751494.
64. Montemurro F, Ueno NT, Rondon G, Aglietta M, Champlin RE. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer 1(3):197-209; discussion 210, 10/2000. PMID: 11899644.
65. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92(3):225-33, 2/2000. PMID: 10655439.
66. Braunschweig I, Mirza NQ, Rondon G, Lauppe J, Mehra R, Gajewski J, Korbling M, Huh YO, Geisler D, Gee AP, Champlin R, Przepiorka D. High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. Cytotherapy 2(2):105-10, 2000. PMID: 12042047.
67. Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersio J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G, Jr, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RA. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 91(9):3509-17, 5/1998. PMID: 9558412.
68. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16(3):986-93, 3/1998. PMID: 9508181.
69. Rahman Z, Champlin R, Rondon G, Frye D, Valero V, Mehra R, Hortobagyi G. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 24:S17-77-S17-80, 10/1997. PMID: 9374100.
70. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12):4531-6, 6/1997. PMID: 9192777.
71. Rondon G, Giralt S, Pereira M, Van Besien K, Mehra R, Champlin R, Andreeff M. Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma 25(5-6):463-7, 5/1997. PMID: 9250816.
72. van Besien KW, de Lima M, Giralt SA, Moore DF, Jr, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19(10):977-82, 5/1997. PMID: 9169641.
73. Johansen MJ, Madden T, Mehra RC, Wood JG, Rondon G, Browne V, Newman RA, Champlin RE. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 15(4):1481-91, 4/1997. PMID: 9193344.
74. Hester J, Bojko P, Rondon G, Champlin R. Integration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs. Transfus Sci 17(4):585-90, 12/1996. PMID: 10168556.
75. Rondon G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin R. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18(3):669-72, 9/1996. PMID: 8879640.
76. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86(11):4337-43, 12/1995. PMID: 7492795.
77. Giralt S, O’Brien S, Talpaz M, van Besien K, Chan K, Rondón G, Andersson B, Mehra R, Khouri I, Estey E, and Champlin R. Alpha Interferon and Interleukin-2 as Treatment for Leukemia Relapse After Allogeneic Bone Marrow Transplantation. Cytokines and Molecular Therapy 1/2:115-122, 1995.
78. Hester JP, Rondón G, Huh YO, Lauppe J, Champlin RE, and Deisseroth AB. Principles of Bone Marrow Processing and Progenitor Cell/Mononuclear Cell Concentrate Collection in a Continuous Flow Blood Cell Separation System. Journal of Hematotherapy 4:299-306, 1995.
79. Rondón G, Murillo J, Guzmán M, Istúriz R, Otero C, López G and Flores A. Actividad comparativa in vitro de norfloxacina, betalactamicos y aminoglicosidos contra cepas de enterobacterias y Pseudomonas Aeruginosa. Archivos Venezolanos de Farmacología y Terapéutica médica 4:417-420, 1985.

Grant & Contract Support

Title: Improving Cord Blood Transplantation
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Elizabeth Shpall
Duration: 9/22/2011 - 8/31/2016
Title: MIRA-Cellular Therapy for Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Regulatory
Principal Investigator: Richard Champlin
Duration: 7/1/2011 - 6/30/2016
Title: Long-term Cancer Survivor Health Promotion Needs and Disseminated Model Care
Funding Source: Fred Hutchinson Cancer Research Center
Role: Collaborator
Principal Investigator: Karen Syrjala
Duration: 12/1/2009 - 11/30/2014
Title: Alloreactive NK Cells
Funding Source: Commonwealth Foundation
Role: Co-Investigator
Principal Investigator: Richard Champlin
Duration: 9/1/2009 - 8/31/2013
Title: Improving the Outcomes of Stem Cell Transplantation
Funding Source: NIH/NHLBI
Role: Co-Investigator
Principal Investigator: Alousi
Duration: 6/5/2002 - 6/30/2017
Title: Therapy of CML--Core A
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Richard Champlin
Duration: 2/12/1997 - 6/30/2016

Last updated: 8/25/2015